Biomarkers and Early Detection Research: Bioinformatics and Omics

A01 Genome-wide changes in expression of small RNAs in human testis cancer tissue. Trine Rounge, Cancer Registry of Norway, Oslo, Norway.

A02 Integrative analysis identifies differential miRNA expression in HPV-positive head and neck squamous cell carcinoma including mir-9 overexpression and corresponding downregulation of the target YAP1. Claudia Heymach, University of Texas MD Anderson Cancer Center, Houston, TX, United States.

Biomarkers and Early Detection Research: Biomarkers of Cancer Susceptibility

A03 ERβ expression and breast cancer risk prediction for women with atypias. Tina Hieken, Mayo Clinic, Rochester, MN, United States.

A04 Menopausal vasomotor symptoms and incident breast cancer risk in the Study of Women’s Health Across the Nation. Vicki Hart, University of Massachusetts Amherst, Amherst, MA, United States.

A05 Menopausal vasomotor symptoms and mammographic density in the Study of Women’s Health Across the Nation. Vicki Hart, University of Massachusetts Amherst, Amherst, MA, United States.

A06 Elucidating the associations of inflammation with cancer risk and mortality using an inflammatory score: Results from a prospective cohort study. Adetunji Toriola, Washington University School of Medicine, St. Louis, MO, United States.

A07 Methylation of RARB in pre-diagnosis benign tissue and risk of disease progression in men subsequently diagnosed with prostate cancer. Benjamin Rybicki, Henry Ford Hospital, Detroit, United States.

A08 Lipid biomarkers and cancer risk: Long term observational follow-up of cancer in the Women’s Health Study. Paulette Chandler, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, United States.

A09 The relationship between DNA methylation in one-carbon metabolism genes and colorectal adenoma risk. Vikki Ho, University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.

Biomarkers and Early Detection Research: Biomarkers of Carcinogen Exposure

A10 Exposure to heterocyclic aromatic amines, genetic susceptibility and bulky DNA adduct levels in blood leukocytes. Vikki Ho, University of Montreal Hospital Research Centre, Montreal, Quebec, Canada.
Biomarkers and Early Detection Research: Biomarkers of Premalignant Lesions

A11 Airway gene expression indicates an increase in oxidative phosphorylation in the field of injury of individuals with premalignant lesions. Sarah Mazzilli, Boston University, Boston, MA, United States.

A12 Identification of novel candidate serum metabolite biomarkers for distinguishing between gastro-esophageal reflux disease, Barrett’s esophagus, and high-grade dysplasia/esophageal adenocarcinoma. Matthew Buas, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Biomarkers and Early Detection Research: Imaging


Biomarkers and Early Detection Research: Molecular Diagnostics

A14 Role of miRNAs as biomarker for the anti-tumoral activity of the plant derived polyphenol Curcumin. Beatrice Bachmeier, Inst. of Laboratory Medicine, Ludwig-Maximilians-University, Munich, Germany.

Biomarkers and Early Detection Research: Other

A15 Immunohistochemical patterns of the breast developmental gene, ELF5, reveals differential expression in high grade hormone receptor negative clinical breast cancer. Teresa Rose-Hellekant, University of Minnesota Medical School, Duluth, MN, United States.

Clinical Prevention Trials (by Organ Site): Breast Cancer


Clinical Prevention Trials (by Organ Site): Head and Neck Cancers

A19 Enhanced curcumin bioavailability through localized microgranular formulation in healthy and cancer treatment cohorts. Brian Latimer, LSUHSC, Shreveport, United States.

Clinical Prevention Trials (by Organ Site): Prostate and Other Genitourinary Tract Cancers

A20 A phase II randomized, presurgical placebo-controlled trial of polyphenon E in bladder cancer patients to evaluate bladder tissue levels of EGCG and biomarkers of growth and apoptosis. Jason Gee, Lahey Hospital and Medical Center, Burlington, MA, United States.
**Metformin Prevention and Treatment Trials**

A21 A Phase IIa trial of Metformin for colorectal cancer risk reduction among patients with a history of colorectal adenomas and elevated body mass index. Jason Zell, University of California Irvine, Irvine, CA, United States.

A22 Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. Andrea DeCensi, E.O. Ospedali Galliera, Genoa, GE, Italy.

A23 Cancer outcomes in the diabetes prevention program outcomes study. Brandy Heckman-Stoddard, National Cancer Institute, Rockville, MD, United States.

A24 Integration of tumor metabolomics, cancer genome sequencing and dynamic functional imaging to assess the metabolic effects of metformin in breast cancer. A. Harris, University of Oxford, Oxford, United Kingdom.

**Epidemiology/Lifestyle Factors: Behavioral Epidemiology**

A25 Television watching, other sedentary behaviors and colorectal cancer survival in men. Yin Cao, Harvard University, Boston, MA, United States.

A26 Relative influence of home and school environments on specific dietary behaviors among postpartum, high-risk teens. Megan Clarke, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, United States.

**Epidemiology/Lifestyle Factors: Cancer in Aging Populations**


**Epidemiology/Lifestyle Factors: Cancer in Minority and Medically Underserved Populations**


A29 Racial disparities in prostate cancer: Estimating the role of diet, lifestyle, and genetic factors among African-American and Caucasian-American men. Sam Peisch, Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, United States.

A30 Breast cancer Family-based Intervention Trial. Katherine Infante, Columbia University Medical Center, New York, NY, United States.

**Epidemiology/Lifestyle Factors: Diet and Cancer**

A31 Correlations between diet, gut microbiota and epithelial methylation pattern with CRC risk. Volker Mai, University of Florida, Gainesville, FL, United States.

A32 Dairy intake in relation to disease-specific and total mortality after prostate cancer diagnosis. Meng Yang, Department of Nutrition, Harvard School of Public Health, Boston, MA, United States.

A33 Pizza and pasta consumption levels in relation to lycopene and other antioxidant nutrients status among a low-income population in Southeast USA. Yuan Zhou, Meharry Medical College, Nashville, Tennessee, United States.
A34 Association of nut consumption and lung cancer risk in a large population-based case-control study. Tram Lam, National Cancer Institute, Rockville, Maryland, United States.


Epidemiology/Lifestyle Factors: Exercise and Prevention

A36 Recreational physical activity and the risk of pancreatic cancer in the California Teachers Study. Kayo Togawa, Beckman Research Institute of City of Hope, Duarte, California, United States.

A37 Feasibility of repeat physical activity measurement among colorectal cancer patients by accelerometry and associations with plasma 25(OH)D levels. Stephanie Tosic, National Center for Tumor Diseases (NCT) and German Cancer Research Center (DKFZ), Heidelberg, Germany.

Epidemiology/Lifestyle Factors: Familial and Genetic Epidemiology

A38 Role of MC1R variants in childhood and adolescent melanoma. Sara Raimondi, European Institute of Oncology, Milan, Italy.

A39 Meta-analysis on Vitamin D Receptor polymorphisms and colorectal cancer risk. Sara Gandini, European Institute of Oncology, Milan, Italy.

A40 Multiple locations on 8q24 and 6p21-22 and rare variants associated with gastric cancer susceptibility in a Korean population. Jeongseon Kim, National Cancer Center, Goyang, Rep. of Korea.

A41 Known susceptibility SNPs for sporadic prostate cancer play a similar role in hereditary prostate cancer. Lambertus Kiemeney, Radboudumc, Nijmegen, Netherlands.

Epidemiology/Lifestyle Factors: General Epidemiology and Biostatistics

A42 Adolescent inflammation and body mass index in relation to colorectal cancer risk. Elizabeth Kantor, Harvard School of Public Health, Boston, MA, United States.

A43 Population attributable risk of postmenopausal breast cancer according to known and modifiable breast cancer risk factors. Rulla Tamimi, Brigham and Women's Hospital, Boston, MA, United States.

Epidemiology/Lifestyle Factors: Obesity, Metabolism, and Cancer

A44 Association between BMI at treatment initiation and cancer survival across multiple SWOG trials. Heather Greenlee, Columbia University, New York, NY, United States.

A45 The association between type 2 diabetes mellitus and incidence of renal cell carcinoma (RCC) and fatal RCC in two prospective cohorts. Rebecca Graff, Harvard School of Public Health, Boston, MA, United States.

A46 Body mass index, waist circumference, and the risk of colorectal adenomas: Black women’s health study. Chiranjeev Dash, Georgetown Lombardi Comprehensive Cancer Center, Washington, DC, United States.
Epidemiology/Lifestyle Factors: Tobacco and Cancer

A47 Meta-analysis of MTHFR polymorphisms in lung cancer: Population health and mutations in the world. Hsiao-Ling Chen, Department of Nursing, College of Medicine, National Taiwan University, Taipei, Taiwan.

Epidemiology/Lifestyle Factors: Other Molecular Epidemiology

A48 Serum biomarkers of habitual coffee consumption may provide insight into the mechanism underlying the association between coffee consumption and colorectal cancer. Kristin Guertin, Division of Cancer Epidemiology & Genetics, National Cancer Institute, Rockville, MD, United States.

A49 Meta-analysis of vitamin D–binding protein and cancer risk. Sara Gandini, European Institute of Oncology, Milan, Italy.

Epidemiology/Lifestyle Factors: Other Risk Factors

A50 Impact of indoor tanning and MC1R genotype on basal cell carcinoma risk in young people. Susan Mayne, Yale School of Public Health, New Haven, CT, United States.

A51 Mammographic breast density and breast cancer risk: Interactions of percent density, absolute dense and non-dense areas with breast cancer risk factors. Lusine Yaghjyan, University of Florida, Gainesville, FL, United States.

A52 Oral contraceptive use and risk of colorectal polyps in a colonoscopy based study in western Washington state. Sheetal Hardikar, Fred Hutchinson Cancer Research Center, Seattle, WA, United States.

Preclinical and Translational Prevention Studies (by Organ Site): Breast Cancer

A53 Benefits of midlife calorie restriction on mammary tumor development in moderately high fat fed mice. Michael Grossmann, Hormel Institute, University of Minnesota, Austin, MN, United States.

Preclinical and Translational Prevention Studies (by Organ Site): Colon and Other Gastrointestinal Cancers

A54 Possible targets of metformin in colorectal cancer. Amikar Sehdev, University of Chicago, Chicago, IL, United States.

Preclinical and Translational Prevention Studies (by Organ Site): Lung Cancer

A55 Mapping the airways: The fate of bronchial epithelium in long term heavy smokers. Kathryn Matney, University of Colorado AMC, Aurora, CO, United States.

Preclinical and Translational Prevention Studies (by Organ Site): Pediatric Malignancies

A56 Metformin targets Rho GTPases to inhibit neuroblastoma cell growth; implications in the treatment of neuroblastoma. Ambrish Kumar, University of South Carolina School of Medicine, Columbia, SC, United States.

A57 ETV6-RUNX1 in urban newborns and young children: Association with Polycyclic Aromatic Hydrocarbon (PAH) DNA adducts in cord blood. Manuela Orjuela, Columbia University, New York, New York, United States.
Preclinical and Translational Prevention Studies (by Organ Site): Prostate and Other Genitourinary Tract Cancers

A58 Aspirin, NSAIDs and risk of prostate cancer: Results from the REDUCE study. Adriana C Vidal, Duke University, Durham, United States.

A59 Dietary Tomato and Lycopene Inhibition of Prostate Carcinogenesis in the TRAMP Model is β,β-Carotene 9,10-oxygenase (BCO2)-Dependent. Jennifer Thomas-Ahner, The Ohio State University, Columbus, Ohio, United States.